How a skin drug trial could help Peninsula biotech pull off key merger
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Alumis to Present at Leerink's 2025 Global Healthcare Conference
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...
Fierce Biotech15h
Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms
With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...
BioSpace1d
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...
Fierce Biotech10d
Acelyrin doubles down on Alumis merger after deciding Concentra's surprise offer 'not superior'
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...
Alumis Inc. (ALMS) Receives a Buy from H.C. Wainwright
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price ...
Alumis announces data from the OLE of its Phase 2 STRIDE trial
Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...
Alumis (NASDAQ:ALMS) Earns Buy Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS – Free Report) in a report published on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. A ...
BioSpace9d
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger
Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.